Article Information
- Received January 12, 2012
- Revision received August 17, 2012
- Accepted September 11, 2012
- First published November 28, 2012.
- Version of record published November 28, 2012.
Author Information
Author contributions
Author contributions: M.A.C., M.B.-J., and F.M.L. designed research; M.A.C., M.B.-J., A.A.A., J.L.N., and H.M.-C. performed research; M.A.C., M.B.-J., A.A.A., and H.M.-C. analyzed data; M.A.C., M.B.-J., and F.M.L. wrote the paper.
↵*M.A.C. and M.B.-J. contributed equally to this work.
Disclosures
- Received January 12, 2012.
- Revision received August 17, 2012.
- Accepted September 11, 2012.
This work was supported by NIH Grants PPG AG00538 and AG027544 (to F.M.L.) and AG029378 and AG16573 (to M.B.-J,), and NIA Grant F31AG039968 (to M.A.C.). We thank Drs. Charles Glabe and Peter Davies for antibodies and Drs. Lars Lannfelt and Michael Vitek for Arctic/Swedish APP and 4R/2N hTau cDNAs. We also thank Adam Pabst for technical assistance. We thank the University of California, Irvine, Transgenic Mouse Facility and Tom Fielder for producing the transgenic founders of the ArcTau line.
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Frank M. LaFerla, Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697-4545. laferla{at}uci.edu
Online Impact
Article usage
In this issue
